Wang Xiao-Bo, Lin Ying-Li, Li Zhi-Gang, Ma Jian-Hua, Li Jian, Ma Jian-Guo
Department of Urology, Tianjin People's Hospital, Tianjin, China.
J Int Med Res. 2014 Apr;42(2):292-9. doi: 10.1177/0300060513504364. Epub 2014 Feb 24.
To investigate the clinical significance of protocadherin 17 (PCDH17) promoter methylation in bladder cancer.
Methylation-specific polymerase chain reaction was used to examine the promoter methylation status of PCDH17 in tumour tissue specimens obtained from patients with bladder cancer, and in normal bladder epithelial tissue specimens obtained from age- and sex-matched controls. The correlations between methylation status and demographic and clinicopathological parameters, and disease outcome, were assessed.
Methylation of the PCDH17 promoter was detected in 77/115 (67.0%) patients with bladder cancer and 0/43 (0%) of the controls. Methylation was significantly associated with high cancer grade (G3), advanced cancer stage (T2-T4), large tumour diameter (> 3 cm) and tumour recurrence. Methylation was also associated with significantly shorter survival time compared with unmethylated PCDH17 in patients with bladder cancer, and was an independent predictor of overall survival.
PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer.
探讨原钙黏蛋白17（PCDH17）启动子甲基化在膀胱癌中的临床意义。
采用甲基化特异性聚合酶链反应检测膀胱癌患者肿瘤组织标本以及年龄和性别匹配的对照者正常膀胱上皮组织标本中PCDH17启动子的甲基化状态。评估甲基化状态与人口统计学和临床病理参数以及疾病转归之间的相关性。
在115例膀胱癌患者中的77例（67.0%）检测到PCDH17启动子甲基化，而43例对照者中无一例（0%）检测到甲基化。甲基化与高肿瘤分级（G3）、晚期癌症分期（T2 - T4）、肿瘤直径大（> 3 cm）及肿瘤复发显著相关。与膀胱癌患者中PCDH17未甲基化者相比，甲基化还与显著缩短的生存时间相关，并且是总生存的独立预测因素。
PCDH17启动子甲基化与膀胱癌恶性程度密切相关，可作为膀胱癌患者临床转归的独立预测指标。
